Seagen tees up with Dutch I/O outfit, engineers $700M deal for EGFR asset

Amid reports that Merck was going to acquire Seagen, the Seattle company decided to do its own M&A — securing a back-heavy deal. The antibody-drug conjugate powerhouse announced bright and early Monday that it would be shelling out as much as $700 million to LAVA Therapeutics, a Netherlands-based gamma delta…

Click here to view original post